NCI/ADR-RES

NCI/ADR-RES is a cell line derived from the human ovarian cancer cell line OVCAR-8. It is a multi-drug resistant cell line, which is often used in biomedical research to study drug resistance mechanisms and to test new chemotherapeutic agents.

History

The NCI/ADR-RES cell line was developed by the National Cancer Institute (NCI) as part of their efforts to understand and overcome drug resistance in cancer. It was derived from the OVCAR-8 cell line, which was originally isolated from a patient with ovarian cancer. The NCI/ADR-RES cell line was selected for its resistance to adriamycin, a commonly used chemotherapeutic agent.

Characteristics

NCI/ADR-RES cells are characterized by their resistance to multiple chemotherapeutic agents, including adriamycin, vincristine, and vinblastine. This resistance is thought to be due to the overexpression of P-glycoprotein, a protein that pumps drugs out of cells, thereby reducing their effectiveness.

In addition to their drug resistance, NCI/ADR-RES cells also exhibit other characteristics that make them a useful model for studying ovarian cancer. For example, they have a high rate of cell proliferation, which mimics the rapid growth of cancer cells in the body. They also have the ability to form tumors when injected into immunocompromised mice, which allows researchers to study the growth and spread of ovarian cancer in a living organism.

Use in Research

NCI/ADR-RES cells are widely used in biomedical research. They are often used to study the mechanisms of drug resistance in cancer, and to test the effectiveness of new chemotherapeutic agents. In addition, they are used to study the biology of ovarian cancer, including the genes and pathways that are involved in its growth and spread.

File:NCI-ADR-RES cells.jpg

NCI/ADR-RES cells under a microscope

See Also

• Cell line
• Ovarian cancer
• Chemotherapy
• Drug resistance
• P-glycoprotein

References

This cell line related article is a stub. You can help WikiMD by expanding it.

‎